Public Health Emergency - Leading a Nation Prepared
She was a member of the Product Development working group for Biodefense for the NIAID, and was an Advisory Board Member of Optimer Pharmaceuticals, Inc. as well as the Supervisory Board of GPC Biotech. At Optimer, she was involved with the development of fidaxomicin. She is currently on the Supervisory Board of OpGen (formerly Curetis, Germany), a publicly traded, molecular diagnostic company, Ocugen, a publicly traded company focused on gene therapy for ocular diseases, and Aelin Therapeutics, located in Leuven Belgium that uses novel technology to develop cancer and antiinfective products. In 2018 she was appointed as a Scientific Advisor to GARDP (Global Antibiotic Research and Development Partnership, a DNDi/WHO initiative) and became the Chairperson in 2019. In 2020, she was selected as a member of the ACTIV NIH working group for therapeutics and vaccines for COVID-19. She serves as a consultant and scientific advisor to a few other biotechnology companies. She has authored over 250 publications and several reviews, book chapters and served as an editor for books. She is an ad hoc reviewer for several journals and is serves as the Section Editor for the Journal of Antibiotics.
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language | Vulnerability Disclosure Policy
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages